Article | January 14, 2025

Automation And Digital Solutions Can Help You Reach Your mRNA Manufacturing And Sustainability Goals

Source: Cytiva
GettyImages-1356993441 mRNA

The rapid rise of mRNA-based therapies, accelerated by COVID-19 vaccine development, highlights the need for efficient, scalable manufacturing processes. Cytiva’s FlexFactory biomanufacturing process train offers an end-to-end, digital solution tailored for the unique challenges of mRNA therapeutics. Unlike traditional manufacturing, mRNA production often requires small, intensified batches with heightened demands for flexibility, speed, and quality control.

Digital transformation, including the adoption of paperless manufacturing, is critical for improving efficiency, reducing costs, and minimizing risks. Digital tools like electronic batch records and standard operating procedures (eSOPs) streamline data management, ensuring real-time traceability and reducing manual errors. For smaller manufacturers, transitioning to digital early accelerates processes, supports regulatory compliance, and reduces contamination risks, particularly in personalized cancer therapies and other applications.

The FlexFactory platform integrates automation, Chronicle software for paperless documentation, and KUBio modular cleanrooms for rapid deployment. These solutions address manufacturing scalability and adaptability, enabling biomanufacturers to produce high-quality mRNA therapies efficiently. Digitalization also supports sustainability by reducing paper usage, cutting carbon footprints, and minimizing travel with localized manufacturing and virtual training tools.

Incorporating a digital strategy early in the manufacturing process ensures faster tech transfer, reduces documentation burdens, and optimizes workflow across distributed sites. By leveraging digital tools, mRNA manufacturers can overcome the unique challenges of this emerging therapeutic class, meeting regulatory standards while enhancing flexibility, efficiency, and sustainability in drug production.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader